Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Clinical trial NCT00110617 · COMPLETED

Trial details

NCT number: NCT00110617
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Sickle Cell Disease Iron Overload Hemolytic Anemia

Start date: 2005-05-01
Primary completion: 2008-04-01
Enrollment: 212

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.